Nonetheless, OSMRβ overexpression may be a potential clinical marker for cervical cancer patients, HER2 in breast cancer, and an anti-OSMRβ monoclonal antibody could improve outcome for patients with cervical cancer. This evidence concerns the gene OSMR and breast carcinoma.